Doxil

Pharma stocks, especially which have large exposure to United States, saw knee-jerk reaction on Friday after a media report indicated that US prosecutors are undertaking an investigation into the suspected price collusion.

Sun Pharma Q2 PAT seen up 48% to Rs 1340 cr: Poll

Analysts expect profit after tax to grow 48 percent year-on-year to Rs 1,340 crore in the quarter gone by. Its reported PAT for Q2FY13 was Rs 319.6 crore, but there was an exceptional outflow of Rs 583.5 crore on Protonix generic; hence reported PAT stood at Rs 903 crore for that quarter.

Sun Pharma hits record high, CLSA says buy post Doxil issue

The brokerage house sees benefit from Doxil (to treat cancer) shortage in the US and expect the company to make more than USD 150 million from this product in FY14.

Sun Pharma may get windfall gains on cancer drug Doxil

The company began supplying Doxil on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Sun Pharma at new high; hopes of higher sales in key drug

Analysts tracking the sector say Sun Pharma already has 50 percent of the market share in this drug which will get a further boost after this development.

See 20% annual returns from Sun Pharma: IIFL Instl Eq

According to pharma analyst Bino Pathiparampil of IIFL Institutional Equities Sun Pharma could make USD 100 million from Doxil.

Sun Pharma gains further on Credit Suisse overweight report

Sun Pharmaceutical Industries gained as much as 1.65 percent intraday on Wednesday as the research firm Credit Suisse maintained an overweight rating on the stock with a target price of Rs 840.

Sun Pharma gains on US nod for cancer drug

Shares in Sun Pharmaceutical Industries Ltd rose as much as 4.5 percent after the US Food and Drug Administration approved its generic version of ovarian cancer drug Doxil made by Johnson & Johnson in the US market.

Sun Pharma surges 4% after Taro's excellent Q3 numbers

Healthcare firm Sun Pharma gained more than 4 percent in early trade after its subsidiary Taro reported excellent numbers in the December quarter.

FDA aapproves generic version of cancer drug Doxil

US health regulators have approved a generic version of the cancer drug Doxil in a move that could ease a months-long shortage that has threatened the lives of thousands of patients.